Typewriter Therapeutics, a portfolio company of AN Venture Partners (ANV), a global bio-venture capital firm and AMED certificated VC, today announced the appointment of Takashi Ichikawa, PhD as Head of R&D Japan.
Typewriter Therapeutics, Inc. is an emerging leader in the development of innovative gene therapies for severe genetic disorders, where patients currently have limited or no clinical options. The company has hired a global team in Chiba and Cambridge to advance its research platform.
Dr. Ichikawa’s role will be to lead R&D at the Japan site, working closely with the US site to deliver an innovative pipeline of drug candidates for patients.
AN Venture Partners (ANV) has been established by a group of experienced venture capitalists from Japan and the United States, who have a wealth of experience in founding and building start-ups. ANV was founded in 2022 in alliance with ARCH Venture Partners. It will primarily focus on sourcing innovative scientific research from Japan and building this into global biotech companies.
“I am delighted to welcome our new colleague,” said Ken Horne, Managing Partner of ANV and Chief Executive Officer of Typewriter. “Securing someone with Takashi’s experience and reputation is exciting news for us. He will bring structure, focus and new ideas to our research efforts. It is a testimony of Typewriter’s potential that we have been able to attract someone of this caliber to switch from a major pharma company to join our startup.”
"I am thrilled to be joining Typewriter, which I believe is developing a genuinely novel approach to combatting severe genetic disorders,” said Dr. Ichikawa. “After spending my whole career in a big organization and mostly in management roles, I am looking forward to the challenges of working at a startup, where we all have to get our hands dirty and do something different every day.”
